1 Guidance

1 Guidance

1.1 Lenalidomide is recommended as an option, within its marketing authorisation, that is for treating transfusion‑dependent anaemia caused by low or intermediate‑1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. It is recommended only if the company provides it according to the commercial arrangement.

  • National Institute for Health and Care Excellence (NICE)